DeepBio has received authorization from the University of Utah’s ethics committee to undertake real world research with ARUP Laboratories to verify the performance of its AI-based prostate cancer diagnostic software.
The business plans to evaluate the effectiveness of DeepDx-Prostate in a real-world situation at the University of Utah ARUP Laboratories with three pathologists who will give a preliminary diagnostic of the slides of core needle biopsy samples of the prostate using a microscope.
CEO Kim Sun-woo talks about AI based solution
Pathologists will thereafter re-examine the same slides using the conventional diagnostic approach as well as DeepDx-Prostate to see if DeepDx-Prostate may help pathologists diagnose cancer more accurately and efficiently.
“Most of the studies that evaluate the performance of AI-based medical solutions are done retrospectively based on current diagnosis data,” stated DeepBio CEO Kim Sun-woo. “This prospective study is important because it can confirm DeepDx-overall Prostate’s effectiveness in a real-world scenario, and we expect our solution to give pathologists with faster and more consistent diagnostic aid when used in the field.”
The study’s primary investigator, Beatrice Knudsen, is the Medical Director of Digital and Computational Pathology at ARUP Laboratories and she stated, “We have high expectations for the impact of DeepDx-Prostate in the clinical practice environment and anticipate the study to draw data on how pathologists can use AI-based solutions to enhance efficiency and accuracy of diagnosis.”
Plans of future collaboration
Since the university approved the cooperative research arrangement in May, DeepBio expects to collaborate with ARUP Laboratories on a variety of cancer diagnosis, prognosis, and prediction investigations.
The company is collaborating with companies that develop pathology image management systems to carry out joint studies with numerous leading universities in the United States and internationally, including Stanford University.
It is also making preparations to provide services to more pathologists by collaborating with companies developing pathology image management systems.
